Abstract
The activation of T cells depends upon two signals, antigen-specific signal through the T cell receptor and nonantigen- specific costimulatory signal through antigen present cell surface molecules. In clinical transplantation, activated T cells orchestrate the immune response and result in allograft acute rejection. Allograft chronic rejection is also a serious complication and a major cause of late allograft loss after the transplantation. Costimulatory molecules involve in determining T cell activation, cytokine production, vascular endothelial cell damage, and induction of transplant tolerance. An emerging therapeutic strategy provides methods for inhibiting undesired T-cell activation, proliferation and function by blocking costimulatory interactions. This review article describes the roles of costimulation pathways in the progression of acute and chronic allograft rejection, particularly focuses on the recent development and application of costimulatory blockers in experimental and pre-clinical transplantation.
Keywords: Allograft rejection, CD28-B7, CD40-CD40L, costimulation interactions, thrombosis, transplant tolerance
Current Drug Safety
Title: New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Volume: 4 Issue: 2
Author(s): Anlun Ma, Liangyan Zhang, Xiliang Wang and Huifang Chen
Affiliation:
Keywords: Allograft rejection, CD28-B7, CD40-CD40L, costimulation interactions, thrombosis, transplant tolerance
Abstract: The activation of T cells depends upon two signals, antigen-specific signal through the T cell receptor and nonantigen- specific costimulatory signal through antigen present cell surface molecules. In clinical transplantation, activated T cells orchestrate the immune response and result in allograft acute rejection. Allograft chronic rejection is also a serious complication and a major cause of late allograft loss after the transplantation. Costimulatory molecules involve in determining T cell activation, cytokine production, vascular endothelial cell damage, and induction of transplant tolerance. An emerging therapeutic strategy provides methods for inhibiting undesired T-cell activation, proliferation and function by blocking costimulatory interactions. This review article describes the roles of costimulation pathways in the progression of acute and chronic allograft rejection, particularly focuses on the recent development and application of costimulatory blockers in experimental and pre-clinical transplantation.
Export Options
About this article
Cite this article as:
Ma Anlun, Zhang Liangyan, Wang Xiliang and Chen Huifang, New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788172991
DOI https://dx.doi.org/10.2174/157488609788172991 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activin-A: A New Piece in the Puzzle of Tolerance in Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Small Molecule and Biologic Modulators of the Immune Response to Hepatitis C Virus
Mini-Reviews in Medicinal Chemistry Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Protein-Protein Interaction Inhibition (2P2I): Fewer and Fewer Undruggable Targets
Combinatorial Chemistry & High Throughput Screening The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Bisphosphonates-Anti-Inflammatory Properties
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protective Antiviral Antibodies that Lack Neutralizing Activity: Precedents and Evolution of Concepts
Current HIV Research From TGF-β to Cancer Therapy
Current Drug Targets Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Current Topics in Medicinal Chemistry